AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01050660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fat emulsion
Description: An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
Study NCT01050660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction of intravenous fat emulsion to 1 gm/kg/d
Description: Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
Study NCT03563248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle
Study NCT03563248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle
Study NCT03563248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan is a drug that is used to lower blood pressure
Study NCT03563248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an antibody that may cause programmed cell death of cancer cells
Study NCT03563248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation therapy is believed to increase the likelihood of response of immunotherapy
Study NCT03563248 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Radiation therapy is believed to increase the likelihood of response of immunotherapy
Study NCT03563248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: definitive surgical resection
Study NCT03563248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: definitive surgical resection
Study NCT01466751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT01466751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT04359953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 2 x per day during 14 days
Study NCT04359953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 2 x per day during 14 days
Study NCT04359953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 2 x per day during 14 days
Study NCT00852644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans
Study NCT00852644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans
Study NCT00852644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks
Study NCT00852644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery
Study NCT03088241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: switch
Description: switch to second-line ART
Study NCT03255278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single GamTBvac vaccination (0.25 dose)
Description: Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
Study NCT03255278 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
Study NCT03255278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (0.25 dose)
Description: Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
Study NCT03255278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (0.5 dose)
Description: Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
Study NCT03255278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (1.0 dose)
Description: Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
Study NCT00783510 — intervention group
Intervention type: BIOLOGICAL
Intervention: adalimumab
Description: As prescribed by treating physician
Study NCT00783510 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: As prescribed by treating physician
Study NCT04150432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon
Description: New device for exhaled propofol concentration measurements
Study NCT01557010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 100mg
Study NCT01557010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 200mg
Study NCT01557010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 300mg
Study NCT01557010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Tablets, oral administration, Placebo
Study NCT02413983 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy conventional incision
Description: This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
Study NCT02413983 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy midline incision
Study NCT02413983 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy transverse incision
Study NCT00984789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)
Description: 0.55mg ethinylestradiol and 2.1mg gestodene
Study NCT00984789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norelgestromin/Ethinylestradiol (EVRA)
Description: 0.6mg ethinylestradiol and 6mg norelgestromin
Study NCT01057628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT01057628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT03095703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
Study NCT01617486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BALANCE
Description: The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
Study NCT01401140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St Thomas
Description: Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Study NCT01401140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol
Description: Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Study NCT03095105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg BIA 6-512
Description: capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
Study NCT01962454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated Water
Description: D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
Study NCT01962454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deuterated Water
Description: D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
Study NCT01962454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
Study NCT01962454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match testosterone enanthate
Description: Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
Study NCT01733355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18] T807
Description: Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
Study NCT00003248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00003248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00148239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Only Intervention
Description: A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
Study NCT00148239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Treatment
Description: Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
Study NCT00148239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants given written educational materials at beginning of study; no treatment beyond this
Study NCT03928470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EsoDuo Tab. 20/800mg
Description: Nexium Tab. 20mg
Study NCT03928470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EsoDuo Tab. 20/800mg
Description: Nexium Tab. 20mg
Study NCT03085069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT02424669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALS Functional rating Scale-revised (ALS FRS-R)
Study NCT02424669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow vital capacity
Study NCT02424669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02424669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study NCT02424669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebrospinal Fluid (CSF) sample
Study NCT01137630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K40a
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
Study NCT01137630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K40b
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
Study NCT01137630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
Study NCT02523586 — intervention group
Intervention type: OTHER
Intervention: Oxygen administration
Description: Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
Study NCT00446394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources and Activities for Life Long Independence (RALLI)
Description: Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
Study NCT00446394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Walking program (SW)
Description: Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
Study NCT01827501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulsioflexTM Monitoring
Description: Fluid and catecholamine management according to PulsioflexTM measurements
Study NCT02061995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREOB® Intravenous Infusion
Description: Each patient will undergo a single intravenous administration of PREOB®.
Study NCT02221076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE)
Description: Real-time microscopic imaging of living tissue during the standard procedure
Study NCT02935738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Description: Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
Study NCT01435993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: Intravenous infusion
Study NCT01435993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: placebo intravenous infusion
Study NCT00622934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: 300mg/kg erythropoietin 3 times on the first week of admission
Study NCT00622934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04072770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea
Description: Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
Study NCT04072770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
Study NCT02316444 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine
Description: An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
Study NCT02798523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate(Solu-Medrol)
Description: Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried.
Study NCT02798523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone (Advantan emulsion 0 /1%)
Description: 1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
Study NCT02481765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition transcranial direct current stimulation
Study NCT00469508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 400mg pills taken orally daily for 12 wks.
Study NCT00469508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg pills taken orally daily for 12 wks
Study NCT00723658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00723658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT00723658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Study NCT00723658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02024464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
Study NCT02024464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Trabecular Micro Bypass
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
Study NCT02024464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract removal and intraocular lens (IOL) implantation
Description: Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects